ClinicalTrials.gg
CompletedNCT02460432Updated Apr 11, 2017

Comparison of Drug Eluting Stent and Covered Metal Stent in Malignant Biliary Obstruction (MIRA III)

An interventional study of Paclitaxel-eluting metal Stent and Covered Metal Stent in Biliary Neoplasms, Biliary Obstruction and Pancreatic Neoplasms, sponsored by Taewoong Medical Co., Ltd.. Completed at 5 sites in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2017-04-11.

Sponsored by Taewoong Medical Co., Ltd. (part of Olympus Corporation) · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 198 studies in Pancreatic Neoplasms with a site in Korea, Republic of — 43 open to participants now, 63 under way, 10 of them phase 3. Pancreatic Neoplasms · Korea, Republic of.

Enrollment
77th of 164
106 · median 100
Started
2015
with 8 others
No phase
34 of 198
2 open now
Registered
48th of 198
by date

Among the 198 studies in Pancreatic Neoplasms with a site in Korea, Republic of, this one is the 77th largest by enrollment of the 164 interventional ones that give a count, is one of 9 that started in 2015, is one of 34 with no phase, and was the 48th registered.

Pancreatic Neoplasms

3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

43 of the 198 studies in Pancreatic Neoplasms with a site in Korea, Republic of are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies in Pancreatic Neoplasms with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The purpose of this study is to compare the effectiveness and safety of Niti-S Mira-Cover III Biliary Stent with Comvi Biliary Covered Stent for the treatment of malignant biliary obstruction.

Read the detailed description

In patients with malignant biliary obstruction, endoscopic placement of biliary stents offers similar technical success rates. Endoscopic retrograde cholangiography (ERCP)-guided stent placement has become the preferred approach to palliate malignant biliary obstruction. The major mechanisms of self-expandable metallic stent (SEMS) occlusion are tumor ingrowth, tumor overgrowth, and epithelial hyperplasia. These mechanisms provide the rationale for developing a drug-eluting stent in order to improve stent patency. Limited data exist regarding outcomes of paclitaxel-eluting stents in malignant biliary obstruction. This study is to prospectively compare the effectiveness and safety of paclitaxel-eluting covered metal stent and covered metal stent for the treatment of malignant biliary obstruction.

03

Conditions studied

  • Biliary Neoplasms
  • Biliary Obstruction
  • Pancreatic Neoplasms

Keywords

  • Drug-eluting Biliary stent
  • Covered metalic stent
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age greater than or equal to 19 years of age
  • Malignant mid or distal biliary obstruction
  • Unresectable cancer
  • Estimated survival greater than or equal to 3 months ( score ≥ 60)
  • Patient willing to provide written and comply with follow-up requirements

Exclusion criteria

Exclusion Criteria:

  • Patients who had undergone surgical biliary drainage
  • Severe bleeding disorder (e.g. coagulopathy)
  • Polypoid lesion or intra-abdominal abscess
  • Female of who are unable to take adequate precautions, are known to be pregnant, or are currently breastfeeding an infant.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
106 participants (actual)

Study arms

  • Experimental
    Paclitaxel-eluting metal Stent

    Niti-S Mira-Cover III Biliary Stent (TaeWoong Medical Co., Ltd. Korea)

    Device: Paclitaxel-eluting metal Stent

  • Active comparator
    Covered Metal Stent

    ComVi Biliary Covered Stent (TaeWoong Medical Co., Ltd. Korea)

    Device: Covered Metal Stent

Interventions

  • DevicePaclitaxel-eluting metal Stent

    Insertion of Niti-S Mira-Cover III Biliary Stent using ERCP

  • DeviceCovered Metal Stent

    Insertion of ComVi Biliary Covered Stent using ERCP

06

What researchers measure

Primary outcomes

  1. Cumulative stent patency during 6months after stent placement

    Stent patency is defined as absence of stent obstruction and confirmed by computed tomography (CT) or ERCP.

    Time frame: 6 month

Secondary outcomes

  1. Stent migration

    Stent migration is defined as an obvious dislodgement from the intended and original implant position and confirmed by radiography, CT, or ERCP.

    Time frame: 6 month

  2. Secondary stent insertion due to recurrent biliary obstruction

    Time frame: 6 month

  3. Mean survival

    Time frame: 6 month

  4. Adverse events

    Time frame: 6 month

07

Study locations

5 sites
  • Inje University Busan Paik Hospital
    Busan, Bokji-ro Busanjin-gu 633-165, Korea, Republic of
  • Seoul National University Hospital
    Seoul, Haehak-ro Jongno-gu 110-744, Korea, Republic of
  • In Ha University Hospital
    Incheon, Inhang-ro Jung-gu 400-711, Korea, Republic of
  • Samsung Medical Center
    Seoul, Irwon-Dong, Gangnam-Gu 130-710, Korea, Republic of
  • Gangnam Severance Hospital
    Seoul, 135-720, Korea, Republic of
08

References and documents

Publications

  • Jang SI, Lee KT, Choi JS, Jeong S, Lee DH, Kim YT, Lee SH, Yu JS, Lee DK. Efficacy of a paclitaxel-eluting biliary metal stent with sodium caprate in malignant biliary obstruction: a prospective randomized comparative study. Endoscopy. 2019 Sep;51(9):843-851. doi: 10.1055/a-0754-5763. Epub 2018 Nov 9. PubMed 30414164 ↗

Individual participant data

Plan to share: Yes — February 12, 2016

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2015, a primary completion of Dec 2016 and a completion of Dec 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2015
First posted
Jun 2, 2015
Start
May 2015
Primary completionActual
Dec 26, 2016
CompletionActual
Dec 26, 2016
Last update
Apr 11, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02460432
Responsible party
Sponsor
First posted
Jun 2, 2015
Start date
May 2015
Primary completion
Dec 26, 2016
Completion
Dec 26, 2016
Last update
Apr 11, 2017

Study contacts

Dong Ki Lee, Ph.D MD
study chair · Gangnam Severance Hospital
Kyu Taek Lee, Ph.D MD
principal investigator · Samsung Medical Center
Sang Hyub Lee, Ph.D MD
principal investigator · Seoul National University Hospital
Don Haeng Lee, Ph.D MD
principal investigator · In Ha University Hospital
Jung Sik Choi, Ph.D MD
principal investigator · Inje University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion